|
|
|
市場調查報告書
基因藥理學與個人化醫療：2009年（市場•課題•預測•主要企業）
Pharmacodiagnostics and Personalized Medicine 2009 (Markets, Challenges, Forecasts and Key Players)
|
基因藥理學與個人化醫療：2009年（市場•課題•預測•主要企業） 是由出版商Kalorama Information在2009年04月所出版的。
這份英文市場調查報告書包含200 pages 價格從美金3500起跳。
此報告書彙整了基因藥理學（Pharmacodiagnostics）市場規模與到2018年為止的收益預測、過去的成功與失敗事例、美國癌治療市場的診斷，以及提供投入市場的主要企業簡介等。報告書之內容摘要如下所示。
第1章 摘要
第2章 基因藥理學以及個人化醫療概要
- 益處
- 隱私與認知
- 生物標記與基因藥理學
- 生物標記種類
第3章 基因藥理學的適用
- 藥物基因體學與基因藥理學
- 歷史基本情報
- 目前的技術
- 要求事項
- 費用對效果
- 適用
- 細胞色素系
- 癌
- 近年的活動
- Amgen
- UAMS的多發性骨髓瘤計畫
- 用於DAKO TOP2A的化驗
- GE與Eli Lilly
- Epigenomics與Abbott
- Celera與Merk
- 規定當局
- 心血管疾病 其他
第4章 基因藥理學的市場預測
- 市場的可能性
- 附屬實驗
- 製藥公司以及診斷製造業者的需求
- 成長課題
- 經濟影響
- 新方法
- 業界合作
- 智慧財產權
- 癌市場預測
- 隱私問題
- 對於了解疾病的恐怖
- 基因組以及SNP分析
- 應考慮的市場實際狀態 其他
第5章 企業摘要
第6章 結論與戰略性建議
第7章 企業簡介
圖表
Abstract
Pharmacodiagnostics are considered the pathway to what has been termed
"personalized medicine," the use of molecular analysis to achieve optimum
medical outcomes in the management of a patient' s disease or predisposition to
disease. As such, personalized medicine promises to bring about a new standard
of healthcare, with the possiblity to increase profits, speed clinical trials,
achieve better clinical results and satisfy patients. But how can companies
earn revenue in this undertaking? What are the likely challenges for pharma
companies and IVD companies? Will the current eocnomy impact this emerging
market?
This report, Pharmacodiagnostics and Personalized Medicine (Markets,
Challenges, Forecasts and Key Players) presents a realistic look at the
promise and pitfalls of personalized medicine, with important data useful for
business planning and marketing efforts, including:
- Current Market Size for U.S. Pharmacodiagnostics
- Forecasted Likely and ' Best Case' Revenue Projections to 2018.
- An Overview of the Concept, Past Successes and Failures.
- Potential Pitfalls for PM Strategies
- Forecasts for Pharmacodiagnostics in the U.S. Cancer Treatment Markets (by
type.)
- Possible Cardiological and Psychiatric Treatment Markets
- 8 Strategic Conclusions And Implications For Entrants in this Market
- Profiles of Key Players in Pharmacodiagnostics
Personalized Medicine has given the diagnostics field a huge boost in terms of
publicity/public attention, revenue potential, and investment interest. Still
questions exist as to how extensive such testing will be and how soon we will
see its growth in clinical applications. There are many hurdles to be
overcome, but researchers are confident they can be. For a thorough
understanding of the impact that personalized medicine could have on
pharmaceutical and diagnostic companies, this report reviews these important
factors: including the key challenges new entrants need to overcome to
establish a revenue stream, genome costs, the likely ' Shotgun Effect' on
Pharmaceutical product lines, the challenge of overcoming privacy concerns in
the wake of the GINA legislation, competing cultures between diagnostic and
pharmaceutical companies, and other factors. There are numerous companies
participating in this market and the number is growing. As part of its unique
analysis, the following companies are profiled:
- Abbott Diagnostics
- Affymetrix, Inc.
- Agilent
- Althea Technologies
- Curidium Medica, PLC.
- Dako
- Gen Probe
- Genzyme Corporation
- Ipsogen
- Lipomics
- Osmetech
- Perlegen Sciences
- Provista Life Sciences
- Qiagen
- Singulex
- Theranostics Health
- Ventana Medical Systems
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY BACKGROUND
- Potential Benefits of Pharmacodiagnostics
- Pittfalls of Personalized Medicine
- Market Considerations
- Drivers
- Impact of Current Economy
- Likely Market Potential
- Assumptions
- Need for Greater Payoff
- Higher Reimbursement
- Royalty Model
- Best Case Market
- Important Considerations
- Increase in Risk
- ' Shotgun' Effect?
- Privacy and Personalized Medicine
- Scope and Methodology
CHAPTER TWO: OVERVIEW OF PHARMACODIAGNOSTICS PERSONALIZED MEDICINE
- Potential Benefits
- Privacy and Public Perception
- Biomarkers and Pharmacodiagnostics
- Types of Biomarkers
CHAPTER THREE: APPLYING PHARMACODIAGNOSTICS
- Pharmacogentics and Pharmacogenomics
- Historical Basis
- Current Techniques
- Requirements
- Cost-effectiveness
- Applications
- The Cytochrome System
- Cancer
- Recent Activities in Pharmacodiagnostics
- Amgen
- UAMS Multiple Myeloma Project
- DAKO Assay for TOP2A
- GE and Eli Lilly
- Epigenomics and Abbott
- Celera and Merk
- bioMerieiux and Ipsen
- Acute Lymphoblastic Leukemia
- Regulatory Agencies
- Applications of Genome More Challenging Than Expected
- Cardiovascular Disease
- RAS polymorphisms With Drug Effectiveness
- Pgp
- Thiazide diuretics
- 825T allele
- HIT
- Statins
- Psychiatry and Pharmacogenetics/Pharmacogenomics
- Drug Development Rescue
- Is Herceptin a Paradigm?
- A Balancing Act between the Players
CHAPTER FOUR: ESTIMATED MARKET POTENTIAL FOR PHARMACODIAGNOSTICS
- On Estimating Market Potential
- Associated Testing
- The Needs of Pharma and of Diagnostic Companies
- Questions Determining Pharmacodiagnostics Growing
- A Partial Change in Attitude
- Economic Impact
- New Approaches
- Industry Collaborations
- Intellectual Property
- Cancer Market Potential Estimate
- Ideal Market Potential - Cancer, Heart Disease, Psychiatric
- Challenges Unique to Pharmacodiagnostics
- Privacy Concerns
- Fear of Learning about Diseases
- Use of Remnant Samples
- Avoiding Pitfalls of Market Calculation
- Pharmacodiagnostics Not Linked to Molecular Diagnostics
- Demonic and SNP Analysis
- Considering Time of Cooperative Development
- Market Realities to Consider
- Possible Tactic: Royalty Model
CHAPTER FIVE: COMPANY SUMMARIES
CHAPTER SIX: CONCLUSIONS AND STATEGIC IMPLICATIONS
- Payoffs
- Who Leads and Who Follows?
- Risk
- Genome Cost Critical
- ' Shotgun' Effect?
- Possibility of Price Increases
- Orphan Drug Markets
- Privacy Issue to Watch
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Table 1-1: Likely Market Potential for Pharmacodiagnostics in the United
States: 2009 - 2013
- Figure 1-1: Likely Market Potential for Pharmacodiagnostics in the United
States: 2009 - 2013
- Figue 1-2: Best Case Market Potential: Potential for Pharmacodiagnostics
in the United States: 2009 - 2013
CHAPTER THREE: APPLYING PHARMACODIAGNOSTICS
- Table 3-1: Pharmacodiagnostics Groups
- Table 3-2: Examples of Inherited or Acquired Variations in Enzymes and
Receptors Affecting Drug Response and Toxicity
- Table 3-3: Frequency of Recessive Traits
- Table 3-4: Existing Cancer Drugs Complimentary to Pharmacodiagnostics
- Table 3-5: Genes Believed to Affect Cardiovascular Drug Metabolism
(Drug/Drug Class, Associated Gene)
CHAPTER FOUR: ESTIMATED MARKET POTENTIAL FOR PHARMACODIAGNOSTICS
- Table 4-1: Markets for Cancer Pharmacodiagnostics if All Patients Tested,
by Cancer Site (Oral, Digestive System, Respiratory System, Bones, Soft
Tissue, Skin, Breast, Genital, Urinary, Eye, Brain, Endocrine, Lymphoma,
Myeloma, Leukemia, Others)
- Figure 4-2: Markets for Cancer Pharmacodiagnostics if All Patients Tested,
by Cancer Site (Oral, Digestive System, Respiratory System, Bones, Soft
Tissue, Skin, Breast, Genital, Urinary, Eye, Brain, Endocrine, Lymphoma,
Myeloma, Leukemia, Others)
- Table 4-2: The Ideal Potential Pharmacodiagnostics Markets for
Therapeutics Addressing Four High-Profile Cancers: 2008
- Figure 4-3: The Ideal Potential Pharmacodiagnostics Markets for
Therapeutics Addressing the Top Four, High-Profile Cancers: 2008
- Figure 4-1 Market If All Cancer Patients Tested Compared to Current Cancer
Diagnostics
- Figure 4-3: The Ideal Pharmacodiagnostics Market (Ideal vs. Likely to
Benefit)
- Figure 4-4: Subset of Ideal Market Likely to Benefit from Pharmaceutical
Intervention (Likely to Benfit vs. Realistic Market)
- Table 4-3: Market Projections for Pharmacodiagnostics in the United
States: 2008 - 2018 (Realistic, Likely Potential, Hi Reimbursement, Absolute
Best Case) millions
- Figure 4-5: Market Projection Trends for Pharmacodiagnostics* in the
United States: 2008 - 2018
|
 |
